AKT1 and cancer: Mechanistic studies found that luteolin synergistic treatment with AA can inhibit down-regulated PI3K/AKT signaling (PI3K, AKT, and p70S6K), JNK/p38 MAPK signaling and FAK signaling and up-regulate ERK signaling, which can induce apoptosis and inhibit the migration of cancer cells to achieve anti-tumor effects.